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Abstract 
Background 
Chromosome changes in the bone marrow (BM) of patients with persistent cytopenia are 
often considered diagnostic for a myelodysplastic syndrome (MDS). Comprehensive 
cytogenetic evaluations may give evidence of the real pathogenetic role of these changes in 
cases with cytopenia without morphological signs of MDS. 
Results 
Chromosome anomalies were found in the BM of three patients, without any morphological 
evidence of MDS: 1) an acquired complex rearrangement of chromosome 21 in a boy with 
severe aplastic anaemia (SAA); the rearrangement caused the loss of exons 2–8 of the 
RUNX1 gene with subsequent hypoexpression. 2) a constitutional complex rearrangement of 
chromosome 21 in a girl with congenital thrombocytopenia; the rearrangement led to RUNX1 
disruption and hypoexpression. 3) an acquired paracentric inversion of chromosome 1, in 
which two regions at the breakpoints were shown to be lost, in a boy with aplastic anaemia; 
the MPL gene, localized in chromosome 1 short arms was not mutated neither disrupted, but 
its expression was severely reduced: we postulate that the aplastic anaemia was due to 
position effects acting both in cis and in trans, and causing Congenital Amegakaryocytic 
Thrombocytopenia (CAMT). 
Conclusions 
A clonal anomaly in BM does not imply per se a diagnosis of MDS: a subgroup of BM 
hypoplastic disorders is directly due to chromosome structural anomalies with effects on 
specific genes, as was the case of RUNX1 and MPL in the patients here reported with 
diagnosis of SAA, thrombocytopenia, and CAMT. The anomaly may be either acquired or 
constitutional, and it may act by deletion/disruption of the gene, or by position effects. Full 
cytogenetic investigations, including a-CGH, should always be part of the diagnostic 
evaluation of patients with BM aplasia/hypoplasia and peripheral cytopenias. 
Keywords 
SAA, Thrombocytopenia, CAMT, RUNX1, MPL, Chromosome structural anomalies, 
Chromosome 1, Chromosome 21 
Background 
In the clinical practice, the finding of an acquired chromosome change in a patient with 
persistent peripheral cytopenia and aplastic or hypoplastic bone marrow (BM), in absence of 
conclusive morphologic features, is usually interpreted as an indicative sign of 
myelodysplastic syndrome (MDS), although the World Health Organization (WHO) 
classification of myeloid neoplasms lists only 14 recurrent anomalies as presumptive 
evidence of MDS [1]. In the years 2000–2011 we performed cytogenetic investigations, as 
part of routine work, in 87 pediatric patients with persistent cytopenia, either uni-, bi- or 
trilinear, during their diagnostic evaluation. In this heterogeneous cohort we found 
monosomy 7 and trisomy 8 in two patients each, all eventually diagnosed as MDS; increased 
chromosome breakage was observed in three cases then diagnosed as Fanconi anaemia (FA); 
an isochromosome for the long arms of chromosome 7 was present in one patient with 
previously undiagnosed Shwachman-Diamond Syndrome; trisomy 8 was found in one patient 
in whom MPL gene mutations demonstrated a congenital amegacaryotic thrombocytopenia 
(CAMT, OMIM # 604998) [2]; a translocation t(8;17)(p21;q25) was present in a patient with 
features of Blackfan-Diamond Anaemia. Moreover, in at least three patients out of 87, 
without any morphological evidence of MDS, a structural chromosome anomaly in the BM 
was the primary event leading to a specific disease. We report here these three patients, and 
suggest that this pathogenetic pathway may be rather frequent. Complex structural anomalies 
of chromosome 21 were present in two of these patients, leading to the disruption or to the 
loss of the RUNX1 gene, with decreased expression and different haematological and clinical 
pictures: severe aplastic anaemia (SAA) and congenital thrombocytopenia. In the third 
patient, a paracentric inversion of chromosome 1 was present, and we postulate that it led to 
aplastic anaemia through position effects on the MPL gene, with severely reduced expression; 
this interpretation turned the diagnosis to CAMT. 
Clinical reports 
Patient 1 
Male child, born in 1997 from non-consanguineous parents, who was diagnosed in 2004 with 
SAA with the following blood counts: RBC 1.66x10
12
/L, Hb 58 g/L, reticulocytes 0.035, 
platelet 11x10
9
/L, WBC 1.8x10
9
/L with 75.4% neutrophils, 11.2% lymphocytes, 12.7% 
monocytes, 0.5% eosinophils, 0.2% basophils. BM biopsy showed decreased cellularity 
(10%) with a picture of severe hypoplasia affecting in particular the granulocytic and 
megakaryocytic lineages. Glycoforin and myeloperoxidase immunostaining showed fair 
conservation of the erythroid series and severe scarcity of the granulopoietic one. The 
diepoxybutane (DEB) test excluded FA. Two cycles of immunosuppressive therapy were 
administered in February and August 2004, according to the protocol “EBMT SAA Working 
Party” consisting of anti-lymphocyte globulin, cyclosporine A, prednisone, and granulocyte-
colony stimulating factor (G-CSF). A slow, progressive improvement was obtained, with no 
further need for transfusions. In August 2006 the patient did fairly well and his blood counts 
were as follows: RBC 3.79x10
12
/L, Hb 121 g/L, platelet 88x10
9
/L, WBC 2.9x10
9
/L, with 
56.4% neutrophils, 32.2% lymphocytes, 0.3% monocytes, 0.1% eosinophils, 0 basophils. BM 
cellularity was increased, with particular regard to the granulocytic and megakaryocytic 
components. The platelet morphology and function were normal, except for the presence of 
spontaneous platelet aggregation. From 2007 to 2009 he remained in fairly good health 
notwithstanding a progressive decrease of Hb, RBC, WBC and platelet values. At the 
beginning of 2009, the patient became gain dependent on platelet and erythrocyte transfusion. 
In June 2009, an HLA-identical unrelated donor was found and the patient underwent 
transplantation of haematopoietic stem cells (HSCT) a month later, after receiving a 
conditioning regimen including fludarabine and low-dose cyclophosphamide. The allograft 
was rejected and a second transplant was performed, employing the HLA-partially matched 
mother as donor. The patient was given a T-depleted allograft, consisting of positively 
selected CD34+ cells after a preparative regimen including treosulfan and fludarabine. This 
second allograft resulted in an engraftment of donor cells, although the haematopoietic 
recovery was incomplete as the patient remained dependent of platelet transfusion and the 
neutrophil count did not exceed 0.20x10
9
/L. For this reason, a second infusion of positively 
selected CD34+ cells was performed in February 2010 without any preparative regimen. 
After this third allograft, the patient recovered normal cell blood counts and he is now alive, 
in complete donor chimerism without any sign of graft-versus-host disease. 
Patient 2 
Female child, born in 2000 from non-consanguineous parents, who was hospitalized due to 
thrombocytopenia discovered at 11 days of life (platelets 54x10
9
/L), and then again 
confirmed at 7 months. She had a small defect of the ventricular septum, which subsequently 
closed spontaneously; cow’s milk intolerance was diagnosed. In the course of the years, her 
thrombocytopenia remained moderate and asymptomatic (e.g. 79x10
9
/L at 7 years, and 
91x10
9
/L at 10 years) and was monitored until 10 years of age, being accompanied by mild 
normocytic anaemia (Hb 100–112 g/L), with normal reticulocyte count, and normal foetal 
haemoglobin. The examination of a BM smear at 8 years of age showed an almost normal 
presence of all cell lines, with some reduction of the erythroid series. A comprehensive 
clinical evaluation failed to reveal any dysmorphisms or other pathological signs. 
The DEB test excluded FA. No mutations of the MPL and RUNX1 genes were present. 
Patient 3 
Male child, born in 2004 from 4
th
 degree consanguineous parents, who was referred for 
aplastic anaemia. He had an elder sister, born in 2000, in whom a diagnosis of aplastic 
anaemia was made at 14 months of age in Tunis, Morocco, with blood counts referred as 
follows: Hb 45 g/L, WBC 3.4x10
9
/L, platelets 7x10
9
/L; no malformative/dysmorphic signs 
were present; her karyotype has been referred as normal, both on BM and on PB. She died at 
the age of two years for a severe infection. Another elder sister, born in 1996, is in good 
health. Then, in 2011, a healthy brother was born. 
The child was examined in August 2007, when his blood counts showed: Hb 62 g/L, RBC 
2.97x10
12
/L, WBC 2.5x10
9
/L with 13% neutrophils, 83% lymphocytes, 0.4% monocytes, 
2.7% eosinophils, 0.4% basophils, platelets 18x10
9
/L. BM trephine biopsy revealed severely 
reduced cellularity, with a few residual myeloid and erythroid elements and no 
megakaryocytes (Mks). Eight months later, a further biopsy revealed complete BM aplasia. 
The DEB test excluded FA. Mutational analysis of the MPL gene, extended to the entire 
gene, was negative. Two polymorphisms in introns of the MPL gene (IVS3 130 + 47 C > T, 
and IVS6 327–41 G > A) were found in homozygosity both in the patient, and in his elder 
healthy sister. The finding that these two variants were shared in heterozygosity by the 
consanguineous parents, indicates that both children inherited from the parents the same MPL 
alleles. In the period 2007–2011, the child was treated with haematopoietic growth factors 
(G-CSF and erythropoietin) and received iron chelation treatment (intra-venous 
desferoxamine). The trilinear cytopenia remained substantially stable, and the child required 
regular transfusions of red blood cell and platelet concentrates. His blood tests consistently 
showed Hb between 70 and 85 g/L, RBC around 2x10
12
/L, WBC 1–2.5x109/L, platelets 15-
40x10
9
/L. Serum thrombopoietin (TPO) level, evaluated in February 2010, was greatly 
increased: 3500 pg/mL (n. v. 6.9-54.4). Platelet surface expression of MPL, evaluated as anti-
MPL/anti-isotype ratio [3] was decreased: 1.28 (n. v. 3.18 ± 0.39). A combined cord blood 
and bone marrow HSCT was performed in July 2011, using the HLA-identical brother born 
in January 2011 as donor. The transplant was followed by complete donor engraftment and 
the progressive achievement of transfusion-independence and of a completely normal blood 
count. 
Results 
Patient 1 
The chromosome analyses on BM revealed a clonal structural anomaly of chromosome 21, 
der(21), present since 2004, a few months after the disease onset, up to June 2009, whereas 
analyses performed at two different dates in 2006 on peripheral blood (PB) 
phytohaemagglutinin (PHA)-stimulated cultures showed a normal karyotype in 100 mitoses 
scored. In most analyses on BM the cells with normal karyotype were the majority, and the 
abnormal cells were few (e.g. 2/20 in February 2006), but this proportion was in fact 
somehow variable (e.g. 10/17 in October 2005; 8/23 in May 2006). Fluorescent in situ 
hybridization (FISH) showed the lack of the signal of the probe CTD-2235K24, which 
recognizes a sequence on chromosome 21 at band q22.12, in the der(21), and this probe was 
then used on interphase nuclei in cytogenetic monitoring: it revealed the presence of the 
der(21) also when no mitoses were observed, and showed that the percentage of abnormal 
cells was 5-50% in the period 2004–2006, and progressively decreased (17-5%) in years 
2006–2008. The decreasing of the der(21) clone paralleled the appearance of a second 
independent clone with an interstitial deletion of the long arms of chromosome 13 as sole 
chromosome anomaly, int del(13)(q12-13q21). In the years 2007–2009, this clone progressed 
in size: from 1/12 to 9/15 mitoses, and from 35/604 to 317/979 nuclei, as evaluated by FISH 
with the probe RP11-1001I7, that recognize sequences at band 13q14.2. 
The banding pattern of the der(21) was interpreted as a partial duplication of the long arms: 
the FISH with the library for WCP painted the entire der(21), and the subtelomeric sequences 
were retained in the expected position as shown by the probe 21qtel07. We started to 
investigate the RUNX1 gene by FISH with the probe “LSI AML1-ETO”, designed to detect 
the translocation t(8;21), recurrent in acute myeloid leukaemia (AML): it revealed a signal of 
RUNX1 on the der(21) less intense compared to the normal 21. So we used a panel of BAC 
probes to investigate the RUNX1 gene (Table 1). Informative results are shown in Figure 1A: 
the exons 2–8 of RUNX1 were absent, the probe recognizing part of the first intron and exon 
2 gave a weak signal, while a more distal probe (RP11 – 203 G22) flanking RUNX1 was 
normally present, as was the probe RP11-79 G23, mapping at a position more close to the 
centromere, in 21q21.3 (not shown in the figure). The duplicated region was demonstrated to 
be also inverted by dual color FISH with two probes mapping in q22.2 and q22.3 (Figure 
1A). Thus, the der(21) was in fact the result of a complex rearrangement with a region 
duplicated and inverted distal to a small interstitial deletion which encompassed most 
RUNX1. 
Table 1 Probes and libraries used for FISH 
Pt Chromosome Probes/libraries Localization/Sequences recognized 
1 13 RP11-1001I7
a
 13q14.2 
21 WCP 21
b
 whole chromosome paint library 
21qtel07
c
 subtelomeric region 
AML1/ETO
d
 designed for t(8;21) 
RP11-79G23
a
 21q21.3 
RP11-203G22
a
 21q22.12 
CTD-2349F18
a
 RUNX1 gene, intron1-exon2 
CTD-2235K24
a
 RUNX1 exons 2–8 
RP11-625E21
a
 21q22.2 
RP11-88N2
a
 21q22.3 
2 21 WCP 21
b
 whole chromosome paint library 
21qtel07
c
 subtelomeric region 
AML1/ETO
d
 designed for t(8;21) 
CTD-2532E17
a
 21p11.2-11.1 
RP11-468N22
a
 21q22.11-22.12 
WI2-1915K14
e
 RUNX1 intron 1 
CTD-2349F18
a
 RUNX1 intron1-exon2 
CTD-2235K24
a
 RUNX1 exons 2–8 
WI2-942D2
e
 RUNX1 exons 2–4 
WI2-605D9
e
 RUNX1 exons 2–5 
WI2-847D7
e
 RUNX1 exon 6 
WI2-542L2
e
 RUNX1 exons 7-8 
3 1 RP11-467K11
a
 1p36.32 
RP11-372C15
a
 1p36.31 
RP11-690E2
a
 1p36.23 
RP11-113C10
a
, RP11-90B12
a
 1p34.2, flanking the MPL gene 
RP11-46G23
a
, RP11-125P23
a
 1p12 
RP11-206H22
a
 1p11.2 
a
 BAC probes, Invitrogen Corporation, Carlsbad, CA, USA 
b
 WCP, Cytocell Technologies, Cambridge, UK 
c
 21 qtel07, Cytocell Technologies, Cambridge, UK 
d
 LSI AML1/ETO dual colour dual fusion translocation probe, Abbott, Abbott Park, IL, USA 
e
 Fosmid probes, kindly provided by Prof. Peter De-Jong, BACPAC Resources Center, 
Childrens Hospital Oakland Research Institute, Oakland, CA, USA 
Patients (Pt), chromosome localization and sequences related to the genes of interest 
recognized. 
Figure 1 Ideograms of the normal chromosome 21, and of the rearranged 21s. The 
der(21) of patient 1 (A), and the inv(21) of patient 2 (B), summarizing the most informative 
FISH results. The following symbols represent the probes related to RUNX1 sequences used, 
and the corresponding exons are indicated in the figure, with signals present, not present or 
weak: # WI2-1915K14,  CTD-2349F18,  WI2-942D2, ♦ WI2-605D9, ∎ CTD-2235K24, 
□ WI2-847D7,  WI2-542L2,  weak signal, NP signal not present. The other BAC probes 
used and mentioned in the text, but not related to RUNX1 sequences, are shown in the figure 
with other symbols 
Array-based comparative genomic hybridization (a-CGH) was performed on DNA from BM 
sampled in June 2007, when the chromosome analysis showed one cell with the der(21), and 
seven with the int del(13) out of 20 mitoses; FISH on nuclei with the probes RP11-1001I7 
(13q14.2), and CTD-2235K24 (RUNX1, exons 2–8) showed 11.5% (52/452) of BM cells 
belonging to the clone with the int del(13), and 9.3% (42/453) to the clone with the der(21). 
The size of these abnormal clones was above the limits of sensitivity for their detection that 
we had previously established [4]. The a-CGH profiles identified precisely the interstitial 
deletion as int del(13)(13q13.3-q21.31) with loss of more than 26 Mb (36 836 026 – 63 185 
558 bp), and the 21q22.12-q22.3 duplication (10.3 Mb, 36 565 301 – 46 897 430 bp), but 
failed to detect the subtle deletion including the exons 2–8 of RUNX1 (Figures 2 A-B). 
Figure 2 a-CGH profiles of the regions of imbalance of patients 1 and 2. A-B: Profiles of 
chromosomes 13 and 21 of patient 1 on DNA from BM sampled in June 2007; C: Profile of 
chromosome 21 of patient 2 on DNA from PB. The profiles shown were obtained with the 
244 K genome-wide system 
The relative expression of RUNX1 was evaluated on BM twice, after two and four years from 
disease onset, when the FISH on nuclei revealed the der(21) in 41% and 5% BM cells, 
respectively; the results showed a strong hypoexpression compared to the controls in the first 
assay (Figure 3A), and a less pronounced hypoexpression in the second one (Figure 3B). 
Figure 3 Relative expression of RUNX1 in the BM of patient 1. Results two years (A), and 
four years (B) after disease onset (2006 and 2008, respectively). The dark grey bars refer to 
the patient and the light grey bars to controls’ average values. Housekeeping control genes 
were ACTB in A, and UBC in B 
Patient 2 
Cytogenetic investigations performed on BM, PHA-PB cultures, and skin fibroblast cultures 
revealed a constitutional rearrangement of chromosome 21 which had a submetacentric 
morphology suggesting a pericentic inversion, inv(21). The investigation by FISH with the 
library for WCP painted completely the inv(21), and the NOR-staining technique 
demonstrated one breakpoint to be inside the region 21p11.1-11.2, not involving the 
satellites. The FISH with the probe “21 qtel07” showed that the inversion did not involve the 
subtelomeric region, while FISH with “LSI AML1/ETO” showed two separate signals for 
RUNX1, one above and one below the centromere, indicating that the other breakpoint was 
localized inside the sequence recognized. We demonstrated that this breakpoint was between 
exons 4 and 5 inside RUNX1, being the signals related to the probes WI2-942D2 and WI2-
605D9 present both in the short and long arms with variable and reduced intensity (Figure 
1B). The probes WI2-1915K14, and CTD-2349F18 were present and not displaced by the 
inversion. The pattern of the pericentric inversion was further defined with the probes CTD – 
2532E17, RP11–468N22, and with probes recognizing RUNX1 exons 6 – 8 (Figure 1B). 
The a-CGH profile (Figure 2C) demonstrated four regions of imbalance, here described in 
order from the centromere to the telomere: 1) a duplication of 36.1 Kb inside the sequence of 
the disrupted RUNX1 gene spanning from 35 138 169 bp to 35 174 269 bp, and including 
exon 5; 2) a duplication of 38 Kb (39 669 148 – 39 707 107 bp); 3) a deletion of 1.4 Mb (43 
014 727 – 44 408 507 bp), confirmed by FISH with the lack of the signal for probe RP11 – 
88 N2, (Figure 1B); 4) a duplication of 162 Kb (46 493 951 – 46 656 014 bp), shown to be a 
benign copy number variation (CNV) by the result of a-CGH performed with the parents’ 
DNA one vs. the other, inherited from the father and included in CNV Database of Genomic 
Variants, updated March 2010 [5]. Thus, the inv(21) resulted in fact in the disruption of the 
RUNX1 gene, with a complex rearrangement including a tiny duplication of part of RUNX1 
itself, and two other imbalances, a deletion and a duplication, both more distal to RUNX1. 
The relative expression of RUNX1 evaluated on BM sample was lower than controls (Figure 
4). 
Figure 4 Relative expression of RUNX1 in the BM of patient 2. The dark grey bar refer to 
the patient and the light grey bar to controls’ average values, UBC was used as control 
Patient 3 
Repeated chromosome analyses performed on BM samples from August 2007 to March 2011 
showed a clonal paracentric inversion of the long arms of chromosome 1, inv(1)(p13p36), as 
sole acquired anomaly. The anomaly was present in 12/15 cells at the first analysis (August 
2007), then in the majority of the cells in repeated analyses from 2008 to 2011. PHA-PB 
cultures showed a normal karyotype (400 mitoses scored), and we ruled out definitely a 
constitutional mosaicism, as a normal karyotype was found also in fibroblasts from a skin 
biopsy, where it was confirmed by 200 nuclei analyzed by FISH with the probe RP11-
372C15, which gave no signal in the inv(1), as better detailed below. 
FISH was performed to investigate the breakpoints of the inversion and to look for the 
possible involvement of the MPL gene, localized in 1p34.2. 
The proximal breakpoint was inside the band 1p12 because the results were the following: the 
signal of the probe RP11-206H22 (1p11.2) was at the normal position, as was the one of the 
probe RP11-125P23 (1p12), which appeared smaller compared to the normal 1 (Figure 5A), 
whereas the signal of the probe RP11-46G23 (1p12) was moved towards the telomere (Figure 
5B). The distal breakpoint was between bands 1p36.23 and 1p36.32, as the signal of the 
probe RP11-467K11 (1p36.32) remained in the expected localization, whereas the one of the 
probe RP11-690E2 (1p36.23) was displaced towards the centromere (Figure 5C). The probe 
RP11-372C15 (1p36.31), in the region of the distal breakpoint failed to show any signal in 
the inv(1) (Figure 5D). Among the results listed, two findings were unexpected: the smaller 
signal of the probe RP11-125P23 (1p12), and the lack of the sequence recognized by the 
probe RP11-372C15 (1p36.31). The possible involvement of the MPL gene was studied by 
FISH with two flanking probes, (RP11-113C10 and RP11-90B12), that demonstrated that the 
gene was not disrupted, in a position closer to the centromere than normal (Figure 6A). 
Figure 5 Mitosis cut-outs with FISH results of patient 3. A: the arrow indicates the signal 
of probe RP11-125P23 (red), at the normal localization, but smaller than the one on the 
normal 1; the red signal on the long arms, both on the normal 1 and on the inv(1), is due do 
cross-hybridization, and the green signal is the one of probe RP11-90B12, flanking the MPL 
gene, used as internal control and displaced towards the centromere on the inv(1); B: the 
arrow indicates the signal of probe RP11-46G23 (red), moved towards the telomere on the 
inv(1); C: the arrow indicates the signal of probe RP11-690E2 (green), moved towards the 
centromere on the inv(1); D: the arrow indicates the inv(1) lacking the signal of probe RP11-
372C15 (green, on the normal 1); the red signal is the one of probe RP11-113C10, flanking 
the MPL gene, used as internal control and displaced towards the centromere on the inv(1) 
Figure 6 Patient 3: FISH for MPL gene and a-CGH results. Probes flanking the MPL gene 
indicate its localization on the inverted chromosome 1, at the right (A); a-CGH profile of the 
short arms of chromosome 1 shows the two deleted regions (B) 
The a-CGH results explained the unexpected FISH findings, showing two deleted regions: a 
segment of 1.65 Mb in 1p36.31 (5 390 817 – 7 024 313), and one of 350 Kb in 1p12 (120 152 
971 – 120 495 484) (Figure 6B). The relative expression of MPL was repeatedly evaluated on 
BM sampled in April 2008, March 2009, October 2009, February 2010, and June 2010, and it 
was always strongly reduced in comparison to controls (Figure 7). 
Figure 7 Patient 3: relative expression of MPL in BM. BM sampled at five different dates 
(light grey columns 1–5), compared to five controls subjects (dark grey column 6: mean 
value ± standard deviation) 
Discussion 
The RUNX1 gene is involved in several different and frequently recurring translocations with 
various partner genes in leukaemia, and point mutations or deletions of this gene are relevant 
as well in the pathogenesis of different types of MDS and leukaemia subtypes [6-9]. 
Germline heterozygous mutations of RUNX1 cause the autosomal dominant disease “familial 
platelet disorder with propensity to AML” (FPD/AML) (OMIM #601399). Therefore, it is not 
surprising that RUNX1 haploinsufficiency due to constitutional chromosome deletions may 
cause a clinical phenotype which includes thrombocytopenia besides intellectual disability 
and other symptoms [10]. Only one case is reported in the literature with a constitutional 
RUNX1 deletion leading to non-syndromic thrombocytopenia with MDS [11]. Patients 1 and 
2 reported here demonstrate that thrombocytopenia or BM hypoplasia with consequent SAA 
may in fact be due to structural anomalies of chromosome 21 involving RUNX1 which are 
not deletions, but complex rearrangements which may also be acquired instead of 
constitutional. 
In detail, the chromosome anomaly in patient 1 was acquired and clonal in BM as shown by 
chromosome analyses and FISH on interphase nuclei. The fact that the der(21) was already 
present at the onset of the SAA provides support for its relevance in the disease aetiology. 
Altogether, our results demonstrate that the der(21) implies a deletion of most of the RUNX1 
gene, besides the inverted duplication of a more distal 10.332 Mb region (Figures 1A-2B): 
the expression of RUNX1 is consequently reduced (Figure 3) and causes defective 
maturation/proliferation of haematopoietic cells and SAA, what does not exclude the possible 
action also of other concomitant factors. During the disease course the abnormal clone varied 
in size within a range from 5% to 50%, as shown from chromosome and FISH analyses, 
without any specific clinico-haematological variation. RUNX1 expression in BM varied in 
parallel with the different size of the clone with the der(21) (Figure 3). Since November 2006 
to November 2008, this abnormal clone decreased in size (to 9%-5%) at the same time of the 
appearance of a new independent clone with the int del(13)(q12-13q21) which, on the 
contrary, increased progressively in size (5%-32%). Worthy of note, similar deletions of 
chromosome 13 are recurrent in myeloproliferative disorders, in particular in polycythaemia 
vera and primary myelofibrosis, but also in MDS and AML [12,13]: no morphological signs 
of overt MDS, however, was ever noticed in our patient 1. 
In patient 2 the complex rearrangement of chromosome 21 led to three regions of imbalance, 
two duplications and one deletion, besides the benign CNV inherited from the father. The 
RUNX1 gene was disrupted by the rearrangement, and a tiny segment including exon 5 was 
duplicated. During the diagnostic procedures, a mutation analysis of RUNX1 had been 
performed, but failed to reveal any change, obviously because no mutation was present in 
exon sequences. So, in this patient the disruption of RUNX1 led to decreased expression 
(Figure 4) and to thrombocytopenia. Being the rearrangement constitutional, we searched 
accurately for possible clinical findings, other than haematological, which might be related to 
the imbalances: when she was 8-year-old, height and weight were between the 25
th
 and the 
50
th
 centile, there was no developmental delay neither mental retardation, and none of the 
dysmorphic/malformative signs described in cases of 21q22 overlapping deletions [14], or 
any other relevant symptoms, were present. 
The definite diagnosis of patient 3 is CAMT. CAMT is an autosomal recessive disorder 
characterized by absent or reduced number of Mks in the BM since birth, extremely elevated 
serum levels of TPO, and very low platelet count that in some cases increases transiently 
during the first year of life [15]. Prognosis of CAMT patients is poor, because all of them 
develop in childhood a tri-linear marrow aplasia that is always fatal when left untreated. In 
our patient, pancytopenia, severely reduced BM cellularity, increased TPO levels and reduced 
platelet expression of TPO receptor, suggested a diagnosis of CAMT. However, homozygous 
or compound heterozygous mutations of the MPL gene, coding for the TPO receptor, that are 
responsible for CAMT [15], were not identified: nevertheless, expression analysis showed a 
very low level of MPL transcript (Figure 7). Moreover, polymorphism analysis showed that 
the patient had inherited from the parents the same alleles of his healthy sister. 
The locus MPL is on the short arms of chromosome 1, in band 34.2, and the BM clonal 
structural anomaly just of the short arms of chromosome 1 may hardly be considered as 
fortuitous. FISH with probes flanking MPL and a-CGH results excluded the disruption of the 
MPL gene (Figure 6). 
We postulate the following pathogenetic mechanism for CAMT in our patient. The 
paracentric inversions are usually considered balanced anomalies, but it has been shown that 
a-CGH applied to search for constitutional anomalies is able to detect a number of 
imbalances undetected with conventional cytogenetic methods, as was the case, e. g., of 10% 
of 13,926 patients with mental disability and apparently normal karyotype reviewed by Sagoo 
et al., 2009 [16]. In patients with apparently balanced constitutional structural 
rearrangements, it has been demonstrated that many cryptic deletions may be found by a-
CGH, more frequently at the breakpoint, with consequent phenotypic abnormalities [17]. So, 
the finding of two cryptic deletions at the breakpoints of the inversion of our patient is not too 
surprising: it is conceivable that this kind of unexpected imbalances may be found in acquired 
anomalies as well, and that position effects may derive from these cryptic imbalances. A 
well-known example of these cryptic rearrangements in an acquired apparently balanced 
translocation, regards chronic myeloid leukaemia with the Ph chromosome by translocation 
t(9;22)(q34;q11), in which deletions in regions flanking the translocation breakpoints are 
frequent, and imply a poor outcome [18]. In constitutional anomalies, firm evidence is 
available of the deregulation of transcripts due to the dissociation from long-range regulatory 
elements, phenomenon usually called position effect: structural anomalies were shown to be 
able to act on specific genes which may be tens of megabases apart from the breakpoints 
identified [19,20]. The a-CGH results in patient 3 showed a distance of about 36.5 Mb from 
the MPL gene to the telomeric breakpoint of the inversion and of about 76.5 Mb the 
centromeric one. The evidences from the literature on constitutional rearrangements concern 
position effects acting even at distance, but always on the chromosome where the breakage 
has took place, in cis, not on its homologue, but in mammals long-range DNA interactions 
were demonstrated acting both in cis and in trans, and causing variable gene expression level 
[21]. So, we postulate that in patient 3 the primary event causing the disease was the acquired 
clonal paracentric inversion, with the loss of the two regions near the breakpoints, and that 
some sequences in the lacking segments impaired the function of the MPL gene by position 
effect, both on the inv(1) and on the normal 1, thus leading to highly reduced expression and 
to acquired CAMT. 
Conclusions 
The three cases here reported lead to the following conclusions as to the role of chromosome 
changes in the pathogenesis of peripheral cytopenias and BM hypoplastic conditions: 1) the 
presence of an acquired clonal anomaly in BM does not suggest per se MDS in patients with 
inconclusive morphologic features: a subgroup of BM hypoplastic disorders, with uni- or 
multi-lineage effects, is directly due to a chromosome structural anomaly in BM which 
causes a specific genic effect. This pathway might be rather frequent: we have on record at 
least another case of thrombocytopenia which is due to a similar mechanism, an adult patient 
with an acquired complex chromosome rearrangement in BM implying deletion of long arms 
of chromosome 11 with loss of the FLI1 gene, and causing a thrombocytopenia of the Paris-
Trousseau type [22]. 2) Structural anomalies of chromosome 21 may impair RUNX1 
expression by deletion or simple disruption of the gene, as in patients 1 and 2, and they may 
be either acquired or constitutional. 3) The chromosome anomaly may act without deletion or 
disruption of the gene, but by impairing the gene expression, as is the case of MPL in our 
patient 3. 
The clinical “take-home message” of our report is that comprehensive cytogenetic 
investigations, if possible including a-CGH, should always be performed for the diagnostic 
evaluation of patients with BM aplasia/hypoplasia and peripheral cytopenias: in this regard, it 
is worth noting that the reduced RUNX1 expression in the abnormal BM cells of patients 1 
and 2 is strictly comparable to that of patients with FPD/AML, in whom a 20-50% risk of 
MDS/AML is expected [23]. 
Methods 
Chromosome analyses were performed in the three patients with routine methods and QFQ-
banding technique on BM direct preparations and 24-48
h
 cultures, on PB unstimulated and 
PHA-stimulated cultures, and, in patients 2 and 3, also on fibroblasts cultured from a skin 
biopsy. In patient 2, also NOR-staining technique was applied. 
FISH on metaphases, and on interphase nuclei was done by standard procedures with 
different probes to define the chromosome anomalies, and to monitor the abnormal clones. 
All the probes used for each patient in the FISH assays are listed in Table 1. 
The a-CGH was performed with the 244 K genome-wide system (Agilent Technologies Inc., 
Santa Clara, CA, USA), according to the manufacturer’s instruction on DNA from BM 
sampled in 2007 of patient 1, on DNA from PB of patient 2 and her parents, and on DNA 
from BM sampled in November 2008 of patient 3. 
The DNA was extracted using the Qiagen Blood and Tissue kit (QIAGEN GmbH, Hilden, 
Germany), and competitor DNA was purchased from Promega (Promega Corporation, 
Madison, WI, USA). Slides were scanned using Agilent’s microarray scanner G2565CA and 
microarray images were analysed using Agilent’s Feature Extraction 10.7.3.1 software, and 
by Agilent’s Genomic Workbench software (5.0.14). All map positions in the results refer to 
the genome assembly hg18. 
In patients 1 and 2 the relative expression of the RUNX1 gene was evaluated on RNA from 
total BM using Applied Biosystems ABI 7000 real-time thermocycler (Life Technologies 
Corporation, Carlsbad, California, USA), and the results were compared with RNA from BM 
of 4 age-matched healthy control subjects who donated haematopoietic cells for 
transplantation of a relative. In patient 1 this assay was performed twice, after two and four 
years from onset (2006, 2008), with Applied Biosystems Taqman assay # Hs_00231079_m1 
for RUNX1, and with endogenous controls which were # Hs_99999903_m1, Actin beta gene 
(ACTB), in the first assay, and # Hs_00824723_m1, Ubiquitin C (UBC) in the second one. 
Patient 2 was examined with the same technique with Applied Biosystems Taqman assay # 
Hs_00231079_m1 for RUNX1, and # Hs_00824723_m1, UBC, as endogenous control. 
In patient 3, the relative expression in BM of the MPL gene was repeatedly evaluated on 
RNA from total BM, sampled at five different dates from April 2008 to June 2010, using the 
same thermocycler as above, with Applied Biosystems Taqman assay # Hs_00180489_m1 
for MPL, and the housekeeping gene HPRT1, Taqman assay # Hs_01003267_m1, as 
normalizer: the results were compared with RNA from BM of 6 age-matched healthy control 
subjects. 
Informed consent to this study was obtained according to the principles of the Declaration of 
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the Ethical Committee of  Fondazione IRCCS Policlinico S. Matteo, Pavia. 
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